From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy.
FGF2
PlGF
VEGF
angiogenesis
bevacizumab
circulating biomarkers
colon cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 May 2020
22 May 2020
Historique:
received:
02
04
2020
revised:
16
05
2020
accepted:
18
05
2020
entrez:
28
5
2020
pubmed:
28
5
2020
medline:
28
5
2020
Statut:
epublish
Résumé
In the last decade, a series of analyses failed to identify predictive biomarkers of resistance/susceptibility for anti-angiogenic drugs in metastatic colorectal cancer (mCRC). We conducted an exploratory preplanned analysis of serum pro-angiogenic factors (SErum aNgiogenesis-cenTRAL) in 72 mCRC patients enrolled in the phase II CENTRAL (ColorEctalavastiNTRiAlLdh) trial, with the aim to identify potential predictive factors for sensitivity/resistance to first line folinic acid-fluorouracil-irinotecan regimen (FOLFIRI) plus bevacizumab. First-line FOLFIRI/bevacizumab patients were prospectively assessed for the following circulating pro-angiogenic factors, evaluated with ELISA (enzyme-linked immunosorbent assay)-based technique at baseline and at every cycle: Vascular endothelial growth factor A (VEGF-A), hepatocyte growth factor (HGF), stromal derived factor-1 (SDF-1), placental derived growth factor (PlGF), fibroblast growth factor-2 (FGF-2), monocyte chemotactic protein-3 (MCP-3), interleukin-8 (IL-8). Changes in circulating FGF-2 levels among different blood samples seemed to correlate with clinical outcome. Patients who experienced an increase in FGF-2 levels at the second cycle of chemotherapy compared to baseline, had a median Progression Free Survival (mPFS) of 12.85 vs. 7.57 months (Hazard Ratio-HR: 0.73, 95% Confidence Interval-CI: 0.43-1.27, Our pre-planned, prospective analysis suggests that circulating FGF-2 levels' early increase could be used as a marker to identify patients who are more likely to gain benefit from FOLFIRI/bevacizumab first-line therapy.
Sections du résumé
BACKGROUND
BACKGROUND
In the last decade, a series of analyses failed to identify predictive biomarkers of resistance/susceptibility for anti-angiogenic drugs in metastatic colorectal cancer (mCRC). We conducted an exploratory preplanned analysis of serum pro-angiogenic factors (SErum aNgiogenesis-cenTRAL) in 72 mCRC patients enrolled in the phase II CENTRAL (ColorEctalavastiNTRiAlLdh) trial, with the aim to identify potential predictive factors for sensitivity/resistance to first line folinic acid-fluorouracil-irinotecan regimen (FOLFIRI) plus bevacizumab.
METHODS
METHODS
First-line FOLFIRI/bevacizumab patients were prospectively assessed for the following circulating pro-angiogenic factors, evaluated with ELISA (enzyme-linked immunosorbent assay)-based technique at baseline and at every cycle: Vascular endothelial growth factor A (VEGF-A), hepatocyte growth factor (HGF), stromal derived factor-1 (SDF-1), placental derived growth factor (PlGF), fibroblast growth factor-2 (FGF-2), monocyte chemotactic protein-3 (MCP-3), interleukin-8 (IL-8).
RESULTS
RESULTS
Changes in circulating FGF-2 levels among different blood samples seemed to correlate with clinical outcome. Patients who experienced an increase in FGF-2 levels at the second cycle of chemotherapy compared to baseline, had a median Progression Free Survival (mPFS) of 12.85 vs. 7.57 months (Hazard Ratio-HR: 0.73, 95% Confidence Interval-CI: 0.43-1.27,
CONCLUSIONS
CONCLUSIONS
Our pre-planned, prospective analysis suggests that circulating FGF-2 levels' early increase could be used as a marker to identify patients who are more likely to gain benefit from FOLFIRI/bevacizumab first-line therapy.
Identifiants
pubmed: 32456056
pii: cancers12051330
doi: 10.3390/cancers12051330
pmc: PMC7281010
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncologist. 2009 Jan;14(1):22-8
pubmed: 19144677
Br J Cancer. 2017 Oct 10;117(8):1099-1104
pubmed: 28926529
Am J Surg. 2001 Sep;182(3):298-304
pubmed: 11587697
N Engl J Med. 2007 Dec 27;357(26):2666-76
pubmed: 18160686
Nat Commun. 2015 Dec 04;6:8792
pubmed: 26635184
Oncotarget. 2016 Jul 12;7(28):44735-44762
pubmed: 27007053
BMC Cancer. 2010 May 14;10:203
pubmed: 20465852
Mol Cancer Ther. 2014 Dec;13(12):3123-36
pubmed: 25319392
Lancet Oncol. 2012 Dec;13(12):1225-33
pubmed: 23168362
Pathol Res Pract. 2002;198(1):1-5
pubmed: 11866204
Clin Exp Metastasis. 2002;19(8):735-8
pubmed: 12553380
Br J Cancer. 2003 Jun 16;88(12):1979-86
pubmed: 12799646
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Mol Cancer Res. 2010 Nov;8(11):1439-52
pubmed: 21047773
PLoS One. 2013 Jul 04;8(7):e66774
pubmed: 23861747
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
EMBO J. 1996 Jan 15;15(2):290-98
pubmed: 8617204
Oncology. 2000 Feb;58(2):169-74
pubmed: 10705245
Cancer Cell. 2012 Jul 10;22(1):21-35
pubmed: 22789536
Mol Cancer. 2017 Feb 16;16(1):41
pubmed: 28209166
J Cell Physiol. 1996 Aug;168(2):294-304
pubmed: 8707865
Cancer Cell. 2007 Jan;11(1):83-95
pubmed: 17222792
Lancet Oncol. 2015 May;16(5):499-508
pubmed: 25877855
Sci Rep. 2020 Feb 19;10(1):2939
pubmed: 32076044
Lancet Oncol. 2015 Aug;16(8):928-36
pubmed: 26115797
Mol Cancer Res. 2013 Dec;11(12):1585-96
pubmed: 24092775
J Clin Invest. 2007 Oct;117(10):2766-77
pubmed: 17909625
Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):E2874-83
pubmed: 26038564
Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78
pubmed: 15863032
PLoS One. 2013 Oct 15;8(10):e77117
pubmed: 24143206
Sci Rep. 2016 Apr 27;6:25195
pubmed: 27117754
J Clin Oncol. 2011 Jan 1;29(1):11-6
pubmed: 20940184
Br J Cancer. 2015 Jun 30;113(1):37-45
pubmed: 26125443
N Engl J Med. 2003 Jul 31;349(5):427-34
pubmed: 12890841
J Ovarian Res. 2012 Sep 19;5(1):23
pubmed: 22989094
Clin Cancer Res. 2010 Aug 1;16(15):3887-900
pubmed: 20554752
J Clin Oncol. 2012 Oct 1;30(28):3499-506
pubmed: 22949147
Biochem Biophys Res Commun. 1993 Mar 15;191(2):535-42
pubmed: 8461011
Cancer Cell. 2005 Oct;8(4):299-309
pubmed: 16226705
Oncotarget. 2017 Dec 4;8(68):113269-113281
pubmed: 29348905
N Engl J Med. 1971 Nov 18;285(21):1182-6
pubmed: 4938153
Am J Pathol. 1999 May;154(5):1381-90
pubmed: 10329591
Cardiovasc Res. 2008 May 1;78(2):315-23
pubmed: 18065770
Br J Cancer. 2013 Apr 2;108(6):1316-23
pubmed: 23449351
PLoS Med. 2008 Jan 29;5(1):e19
pubmed: 18232728
J Pharmacol Exp Ther. 2001 Dec;299(3):1073-85
pubmed: 11714897
Clin Cancer Res. 2013 Apr 1;19(7):1773-83
pubmed: 23307858
J Immunol Methods. 2009 Aug 15;347(1-2):91-2
pubmed: 19394338
Cancer Res. 2010 Feb 1;70(3):1063-71
pubmed: 20103651
BMC Cancer. 2011 Jun 14;11:247
pubmed: 21669012
J Clin Oncol. 2013 Jan 20;31(3):359-64
pubmed: 23233715